Biotech Holdings retains corporate development company
Robert Rieveley, President of Biotech Holdings announced that the company has recently retained Erythana Ventures Corp. to provide assistance with corporate development.
"At the Company's current development point, with our diabetes drug now on the market in Mexico, we have retained Erythana to assist with the realization of our potential, both in terms of corporate activity and market value," Mr. Rieveley said.
"Erythana has a 21-year operating history, working with clients from offices in Vancouver and Calgary. Erythana has been retained by more than 350 corporate, institutional and government clients, in more than a dozen countries. We believe that Erythana and its principal, Si Brown, can offer Biotech valuable assistance with our corporate growth," Mr. Rieveley said.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.